Zai Lab Ltd Stock News

Zai Lab (ZLAB) said the Center for Drug Evaluation ((CDE)) of the National Medical Products Administration ((NMPA)) granted breakthrough therapy designation to repotrectinib for…

--- Potential best-in-class therapy for ROS1-positive metastatic NSCLC and advanced solid tumors --- Potential best-in-class therapy for ROS1-positive metastatic NSCLC and advanced solid tumors

Deciphera (DCPH) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock down is after-hours trading.

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutic

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.

In light of the Asian population celebrating Lunar New Year, five Chinese stocks with high financial strength and owned by at least one of the “Tiger Cub” firms include JD.com Inc. ( JD , Financia

Zai Lab Limited - ADR (ZLAB) shares closed today 14.4% higher than it did at the end of yesterday. The stock is currently down 30.9% year-to-date, down 72.9% over the past 12 months, and up 55.5% over the past five years. Today, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.8%. Trading Activity Shares traded as high as $50.11 and as low as $39.75 this week.Shares closed 73.5% below its 52-week high and 25.0% above its 52-week low.Trading volume this week was 40.5% higher than the 10-day average and 16.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 75.6% The company's stock price performance over the past 12 months lags the peer average by 127.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Andreas Halvorsen (Trades, Portfolio), chief investment officer of Viking Global Investors, disclosed a stake in Amylyx Pharmaceuticals Inc. ( AMLX , Financial) late last week.

Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that

SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutic

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB , HKEX: 9688)), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for margetuximab, an investigational, Fc-engineered monoclonal antibody that targets HER2. The margetuximab NDA is for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease, in combination with chemotherapy. "We are pleased to have NMPA''s acceptance of our NDA for margetuximab, which is the only HER2-targeted agent to have shown a progression-free survival (PFS) improvement versus trastuzumab in SOPHIA, a head-to-head global Phase 3 clinical trial," said Alan Sandler, MD, President and Head of Global Development, Oncology, at Zai Lab. "Both SOPHIA and Zai Lab''s registrational bridging trial support the potential use of margetuximab as an important new treatment option for a very difficult-to-treat patient population.

SHANGHAI, SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical